Journal publications

Export 74 results:
Author Title Type [ Year(Desc)]
Filters: Type is Journal Article  [Clear All Filters]
2005
Pillay D, Green H, Matthias R, Dunn DT, Phillips AN, Sabin CA, Evans B..  2005.  Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis. 192:967-73.
Phillips AN, Dunn DT, Sabin CA, Pozniak A, Matthias R, Geretti AM, Clark J, Churchill D, Williams I, Hill T et al..  2005.  Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS. 19:487-94.
Cane P A, Chrystie I, Dunn DT, Evans B., Geretti AM, Green H, Phillips AN, Pillay D, Porter K, Pozniak A et al..  2005.  Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 331:1368.
2006
Gifford RJM, de Oliveira T, Rambaut A, Myers R.E, Gale C.V, Dunn DT, Shafer R., Vandamme A.M, Kellam P, Pillay D.  2006.  Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity. AIDS. 20:1521-9.
2007
UK Collaborative Group on HIV Drug Resistance, UK Collaborative HIV Cohort Study(UK CHIC), UK Register of HIV Seroconverters.  2007.  Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS. 21:1035-9.
Nebbia G, Sabin CA, Dunn DT, Geretti AM.  2007.  Emergence of the H208Y mutation in the reverse transcriptase (RT) of HIV-1 in association with nucleoside RT inhibitor therapy. J Antimicrob Chemother. 59:1013-6.
Cane P A, Green H, Fearnhill E, Dunn DT.  2007.  Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS. 21:447-55.
Dunn DT, Pillay D.  2007.  UK HIV drug resistance database: background and recent outputs. J HIV Ther. 12:97-8.
2008
Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT.  2008.  The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. J Acquir Immune Defic Syndr. 49:196-204.
Chakraborty R., Smith CJ, Dunn DT, Green H, Duong T., Doerholt K., Riordan A., Lyall H., Tookey P, Butler K. et al..  2008.  HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J. 27:457-9.
Grover D, Copas A, Green H, Edwards SG, Dunn DT, Sabin CA, Phillips AN, Allen E., Pillay D.  2008.  What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? J Antimicrob Chemother. 61:705-13.
Cozzi-Lepri A.  2008.  Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response. HIV Med. 9:27-40.
Assoumou L., Brun-Vezinet F., Cozzi-Lepri A, Kuritzkes D., Phillips AN, Zolopa A., Degruttola V., Miller V., Costagliola D..  2008.  Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. J Infect Dis. 198:470-80.
Dunn DT, Geretti AM, Green H, Fearnhill E, Pozniak A, Churchill D, Pillay D, Sabin CA, Phillips AN.  2008.  Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors. Antivir Ther. 13:771-7.
2009
Hughes GJ, Fearnhill E, Dunn DT, Lycett S, Rambaut A, Leigh Brown A.  2009.  Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom. PLoS Pathog. 5:e1000590.
Harrison LJ, Dunn DT, Green H, Copas A.  2009.  Modelling the association between patient characteristics and the change over time in a disease measure using observational cohort data. Stat Med. 28:3260-75.
Pond S.LKosakov, Posada D., Stawiski E., Chappey C., Poon A.F, Hughes GJ, Fearnhill E, Gravenor M.B, Leigh Brown A, Frost S.D.  2009.  An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1. PLoS Comput Biol. 5:e1000581.
Geretti AM, Harrison LJ, Green H, Sabin CA, Hill T, Fearnhill E, Pillay D, Dunn DT.  2009.  Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis. 48:1296-305.
Hue S, Gifford RJM, Dunn DT, Fearnhill E, Pillay D.  2009.  Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals. J Virol. 83:2645-54.
Gupta R.K, Hill A., Sawyer A.W, Cozzi-Lepri A, von Wyl V., Yerly S, Lima V.D, Günthard HF, Gilks C., Pillay D.  2009.  Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 9:409-17.